Persistent anxiogenic effects of a single or repeated doses of cocaine and methamphetamine: Interactions with endogenous cannabinoid receptor ligands

Behavioural Pharmacology

Volumn 16, Issue 5-6, 2005, Pages 395-404

  Hayase, Tamaki ^a   Yamamoto, Y ^a   Yamamoto, K ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cocaine; Elevated plus maze test; Endogenous cannabinoids; Methamphetamine; Mouse; Neuronal plasticity; Persistent anxiogenic effects

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; AMINE; ANANDAMIDE; CANNABINOID RECEPTOR AGONIST; COCAINE; DOPAMINE DERIVATIVE; ETHER DERIVATIVE; METHAMPHETAMINE; N ARACHIDONYLDOPAMINE; NOLADIN ETHER; UNCLASSIFIED DRUG; VIRODHAMINE;

ANIMAL EXPERIMENT; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; MALE; MAZE TEST; MOUSE; NERVE CELL PLASTICITY; NONHUMAN;

ANALYSIS OF VARIANCE; ANIMALS; ANXIETY; ARACHIDONIC ACIDS; BEHAVIOR, ANIMAL; COCAINE; CYCLOHEXANOLS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GLYCERIDES; INJECTIONS, INTRAPERITONEAL; MALE; MAZE LEARNING; METHAMPHETAMINE; MICE; MICE, INBRED ICR; POLYUNSATURATED ALKAMIDES; RECEPTOR, CANNABINOID, CB1; TIME FACTORS;

EID: 26044463529     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-200509000-00012     Document Type: Article

References (63)

1. Alves SH, Pinheiro G, Motta V, Landeira-Fernandez J, Cruz AP (2004). Anxiogenic effects in the rat elevated plus-maze of 5-HT(2C) agonists into ventral but not dorsal hippocampus. Behav Pharmacol 15:37-43.
2. Arevalo C, De Miguel R, Hernandez-Tristan R (2001). Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacol Biochem Behav 70:123-131.
3. Arnold JC, Topple AN, Hunt GE, McGregor IS (1998). Effects of pre-exposure and co-administration of the cannabinoid receptor agonist CP 55,940 on behavioral sensitization to cocaine. Eur J Pharmacol 354:9-16.
4. Aronson SC, Black JE, McDougle CJ, Scanley BE, Jatlow P, Kosten TR, et al. (1995). Serotonergic mechanisms of cocaine effects in humans. Psychopharmacology (Berl) 119:179-185.
5. Batkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, Harvey-White J, et al. (2004). Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 110:1996-2002.
6. Cancela LM, Basso AM, Martijena ID, Capriles NR, Molina VA (2001). A dopaminergic mechanism is involved in the 'anxiogenic-like' response induced by chronic amphetamine treatment: a behavioral and neurochemical study. Brain Res 909:179-186.
7. Caul WF, Stadler JR, Barrett RJ (1997). Amphetamine-induced withdrawal responding: effects of repeated drug administration. Psychopharmacology (Berl) 133:351-355.
8. Chaperon F, Thiebot MH (1999). Behavioral effects of cannabinoid agents in animals. Crit Rev Neurobiol 13:243-281.
9. Chen JC, Liang KW, Huang YK, Liang CS, Chiang YC (2001). Significance of glutamate and dopamine neurons in the ventral pallidum in the expression of behavioral sensitization to amphetamine. Life Sci 68:973-983.
10. Cole JC, Rodgers RJ (1995). Ethological comparison of the effects of diazepam and acute/chronic imipramine on the behaviour of mice in the elevated plus-maze. Pharmacol Biochem Behav 52:473-478.
11. Costall B, Kelly ME, Naylor RJ, Onaivi ES (1989). The actions of nicotine and cocaine in a mouse model of anxiety. Pharmacol Biochem Behav 33:197-203.
12. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949.
13. De Vries TJ, Shaham Y, Homberg JR, Crombag H, Schuurman K, Dieben J, et al. (2001). A cannabinoid mechanism in relapse to cocaine seeking. Nat Med 7:1151-1154.
14. Ettenberg A, Geist TD (1991). Animal model for investigating the anxiogenic effects of self-administered cocaine. Psychopharmacology (Berl) 103: 455-461.
15. Filip M, Bubar MJ, Cunningham KA (2004). Contribution of serotonin (5-hydroxytryptamine; 5-HT) 5-HT2 receptor subtypes to the hyperlocomotor effects of cocaine: acute and chronic pharmacological analyses. J Pharmacol Exp Ther 310:1246-1254.
16. Fleckenstein AE, Haughey HM, Metzger RR, Kokoshka JM, Riddle EL, Hanson JE, et al. (1999). Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function. Eur J Pharmacol 382:45-49.
17. Ghasemzadeh MB, Permenter LK, Lake R, Worley PF, Kalivas PW (2003). Homer1 proteins and AMPA receptors modulate cocaine-induced behavioural plasticity. Eur J Neurosci 18:1645-1651.
18. Goeders NE (1991). Cocaine differentially affects benzodiazepine receptors in discrete regions of the rat brain: persistence and potential mechanisms mediating these effects. J Pharmacol Exp Ther 259: 574-581.
19. Griebel G, Belzung C, Perrault G, Sanger DJ (2000). Differences in anxiety-related behaviours and in sensitivity to diazepam in inbred and outbred strains of mice. Psychopharmacology (Berl) 148:164-170.
20. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, et al. (2001). 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 98:3662-3665.
21. Harris GC, Aston-Jones G (1993). Beta-adrenergic antagonists attenuate withdrawal anxiety in cocaine- and morphine-dependent rats. Psychopharmacology (Berl) 113:131-136.
22. Harris GC, Altomare K, Aston-Jones G (2001). Preference for a cocaine-associated environment is attenuated by augmented accumbal serotonin in cocaine withdrawn rats. Psychopharmacology (Berl) 156:14-22.
23. Hayase T, Yamamoto Y, Yamamoto K (2000). Stress-related behavioral alterations accompanying cocaine toxicity: the effects of mixed opioid drugs. Jpn J Alcohol Drug Dependence 35:402-414.
24. Hayase T, Yamamoto Y, Yamamoto K (2003). Brain excitatory amino acid transporters (EAATs) and treatment of methamphetamine toxicity. Jpn J Alcohol Drug Dependence 38:498-511.
25. Hliňák Z, Krejči I (2002). MK-801 induced amnesia for the elevated plus-maze in mice. Behav Brain Res 131:221-225.
26. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, et al. (2002). An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 99:8400-8405.
27. Huang YC, Wang SJ, Chiou LC, Gean PW (2003). Mediation of amphetamine-induced long-term depression of synaptic transmission by CB1 cannabinoid receptors in the rat amygdala. J Neurosci 23: 10311-10320.
28. Izzo E, Martin-Pardon R, Koob GF, Weiss F, Sanna PP (2002). Neural plasticity and addiction: PI3-kinase and cocaine behavioral sensitization. Nat Neurosci 5:1263-1264.
29. Julian MD, Martin AB, Cuellar B, Rodriguez De Fonseca F, Navarro M, Moratalla R, et al. (2003). Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia. Neuroscience 119:309-318.
30. Kalivas PW, Sorg BA, Hooks MS (1993). The pharmacology and neural circuitry of sensitization to psychostimulants. Behav Pharmacol 4:315-334.
31. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, et al. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9:76-81.
32. Kotlinska J, Liljequist S (1998). The putative AMPA receptor antagonist, LY326325, produces anxiolytic-like effects without altering locomotor activity in rats. Pharmacol Biochem Behav 60:119-124.
33. Lapin IP (1993). Anxiogenic effect of phenylethylamine and amphetamine in the elevated plus-maze in mice and its attenuation by ethanol. Pharmacol Biochem Behav 44:241-243.
34. Li Y, Kauer JA (2004). Repeated exposure to amphetamine disrupts dopaminergic modulation of excitatory synaptic plasticity and neurotransmission in nucleus accumbens. Synapse 51:1-10.
35. Lienau AK, Kuschinsky K (1997). Sensitization phenomena after repeated administration of cocaine or D-amphetamine in rats: associative and non-associative mechanisms and the role of dopamine in the striatum. Naunyn Schmiedebergs Arch Pharmacol 355:531-537.
36. London ED, Simon SL, Berman SM, Mandelkern MA, Lichtman AM, Bramen J, et al. (2004). Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry 61:73-84.
37. Magendzo K, Bustos G (2003). Expression of amphetamine-induced behavioral sensitization after short- and long-term withdrawal periods: participation of mu- and delta-opioid receptors. Neuropsychopharmacology 28:468-477.
38. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, et al. (2003). CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302:84-88.
39. McGregor IS, Clemens KJ, Van der Rasse G, Li KM, Hunt GE, Chen F, et al. (2003). Increased anxiety 3 months after brief exposure to MDMA ('Ecstasy') in rats: association with altered 5-HT transporter and receptor density. Neuropsychopharmacology 28:1472-1484.
40. Murphy CA, Heidbreder C, Feldon J (2001). Acute withdrawal from repeated cocaine treatment enhances latent inhibition of a conditioned fear response. Behav Pharmacol 12:13-23.
41. Paine TA, Jackman SL, Olmstead MC (2002). Cocaine-induced anxiety: alleviation by diazepam, but not buspirone, dimenhydrinate or diphenhydramine. Behav Pharmacol 13:511-523.
42. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, et al. (2001). An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413:527-531.
43. Porter AC, Felder CC (2001). The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol Ther 90:45-60.
44. Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, et al. (2002). Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301:1020-1024.
45. Prior H, Schwegler H, Marashi V, Sachser N (2004). Exploration, emotionality, and hippocampal mossy fibers in nonaggressive AB/Gat and congenic highly aggressive mice. Hippocampus 14:135-140.
46. Rodgers RJ, Cole JC, Aboualfa K, Stephenson LH (1995). Ethopharmacological analysis of the effects of putative 'anxiogenic' agents in the mouse elevated plus-maze. Pharmacol Biochem Behav 52:805-813.
47. Rogerio R, Takahashi RN (1992). Anxiogenic properties of cocaine in the rat evaluated with the elevated plus-maze. Pharmacol Biochem Behav 43: 631-633.
48. Sajdyk TJ, Shekhar A (1997). Excitatory amino acid receptors in the basolateral amygdala regulate anxiety responses in the social interaction test. Brain Res 764:262-264.
49. Sarnyai Z, Biro E, Gardi J, Vecsernyes M, Julesz J, Telegdy G (1995). Brain corticotropin-releasing factor mediates 'anxiety-like' behavior induced by cocaine withdrawal in rats. Brain Res 675:89-97.
50. Segal DS, Kuczenski R (1997). Repeated binge exposures to amphetamine and methamphetamine: behavioral and neurochemical characterization. J Pharmacol Exp Ther 282:561-573.
51. Shimada T, Matsumoto K, Osanai M, Matsuda H, Terasawa K, Watanabe H (1995). The modified light/dark transition test in mice: evaluation of classic and putative anxiolytic and anxiogenic drugs. Gen Pharmacol 26:205-210.
52. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, et al. (1995). 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215:89-97.
53. Szumlinski KK, Haskew RE, Balogun MY, Maisonneuve IM, Glick SD (2001). Iboga compounds reverse the behavioural disinhibiting and corticosterone effects of acute methamphetamine: Implications for their antiaddictive properties. Pharmacol Biochem Behav 69:485-491.
54. Tella SR (1994). Differential blockade of chronic versus acute effects of intravenous cocaine by dopamine receptor antagonists. Pharmacol Biochem Behav 48:151-159.
55. Ungless MA, Whistler JL, Malenka RC, Bonci A (2001). Single cocaine exposure in vivo induces long-term potentiation in dopamine neurons. Nature 411:583-587.
56. Unterwald EM, Ho A, Rubenfeld JM, Kreek MJ (1994). Time course of the development of behavioral sensitization and dopamine receptor up-regulation during binge cocaine administration. J Pharmacol Exp Ther 270: 1387-1396.
57. Vanderschuren LJ, Schmidt ED, De Vries TJ, Van Moorsel CA, Tilders FJ, Schoffelmeer AN (1999). A single exposure to amphetamine is sufficient to induce long-term behavioral, neuroendocrine, and neurochemical sensitization in rats. J Neurosci 19:9579-9586.
58. Walker JM, Krey JF, Chu CJ, Huang SM (2002). Endocannabinoids and related fatty acid derivatives in pain modulation. Chem Phys Lipids 121:159-172.
59. Wallace MJ, Martin BR, DeLorenzo RJ (2002). Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur J Pharmacol 452:295-301.
60. Wood DM, Lal H (1987). Anxiogenic properties of cocaine withdrawal. Life Sci 41:1431-1436.
61. Zapata A, Chefer VI, Ator R, Shippenberg TS, Rocha BA (2003). Behavioural sensitization and enhanced dopamine response in the nucleus accumbens after intravenous cocaine self-administration in mice. Eur J Neurosci 17: 590-596.
62. Zhang Y, Loonam TM, Noailles PA, Angulo JA (2001). Comparison of cocaine- and methamphetamine-evoked dopamine and glutamate overflow in somatodendritic and terminal field regions of the rat brain during acute, chronic, and early withdrawal conditions. Ann NY Acad Sci 937:93-120.
63. Zorrilla EP, Valdez GR, Weiss F (2001). Changes in levels of regional CRF-like-immunoreactivity and plasma corticosterone during protracted drug withdrawal in dependent rats. Psychopharmacology (Berl) 158:374-381.